{"product_id":"lucifutib-futibatinib","title":"LuciFutib (Futibatinib)","description":"\u003ch2\u003eAbout Futibatinib\u003c\/h2\u003e\u003cp\u003eFutibatinib blocks a protein called FGFR, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor.\u003c\/p\u003e\u003ch3\u003eCholangiocarcinoma\u003c\/h3\u003e\u003cp\u003eIndicated for previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma in adults harboring fibroblast growth factor receptor 2 (\u003ci\u003eFGFR2\u003c\/i\u003e) gene fusions or other rearrangements\u003c\/p\u003e\u003cp\u003e20 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity occurs\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eDose reductions for adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 16 mg qDay\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 12 mg qDay\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 12 mg\/day: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRetinal pigment epithelial detachment (RPED)\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eContinue at current dose and continue periodic ophthalmic evaluation\u003c\/li\u003e\n\u003cli\u003eIf RPED resolves in ≤14 days, continue at current dose\u003c\/li\u003e\n\u003cli\u003eIf not resolving in ≤14 days, withhold; once resolved, resume at previous or lower dose\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHyperphosphatemia\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eSerum phosphate ≥5.5 to ≤7 mg\/dL: Continue at current dose and initiate phosphate-lowering therapy; monitor serum phosphate weekly\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eSerum phosphate \u0026gt;7 to ≤10 mg\/dL\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eInitiate or adjust phosphate-lowering therapy; monitor serum phosphate weekly\u003c\/li\u003e\n\u003cli\u003eReduce dose to next level\u003c\/li\u003e\n\u003cli\u003eIf serum phosphate is ≤7 mg\/dL within 2 weeks after dose reduction, continue at this reduced dose\u003c\/li\u003e\n\u003cli\u003eIf serum phosphate is \u0026gt;7 mg\/dL within 2 weeks, further reduce dose to the next lower level\u003c\/li\u003e\n\u003cli\u003eIf serum phosphate is \u0026gt;7 mg\/dL within 2 weeks after second dose reduction, withhold until serum phosphate is ≤7 mg\/dL and resume at dose before suspending\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eSerum phosphate \u0026gt;10 mg\/dL\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eInitiate or adjust phosphate lowering therapy and monitor serum phosphate weekly\u003c\/li\u003e\n\u003cli\u003eWithhold until phosphate is ≤7 mg\/dL and resume at next lower dose\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue if serum phosphate is \u0026gt;7 mg\/dL within 2 weeks following 2 dose interruptions and reductions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eOther adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3: Withhold until toxicity resolves to Grade 1 or baseline\u003c\/li\u003e\n\u003cli\u003eResume for hematologic toxicities resolving ≤1 week, at dose before suspending\u003c\/li\u003e\n\u003cli\u003eResume for other adverse reactions at next lower dose\u003c\/li\u003e\n\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild to moderate (creatinine clearance [CrCl] 30-89 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (CrCl 15- 29 mL\/min), renal dialysis in end-stage renal disease (CrCl \u0026lt;15 mL\/min): Not studied\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (total bilirubin ≤ULN and AST\u0026gt; ULN, or total bilirubin ≤1.5x ULN and any AST): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eModerate or severe (total bilirubin \u0026gt;1.5x ULN and any AST): Not studied\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797955604523,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-1072.jpg?v=1787022237","url":"https:\/\/xomeds.com\/products\/lucifutib-futibatinib","provider":"XOMEDS","version":"1.0","type":"link"}